A 30-Year History of PLG Applications in Parenteral Controlled Drug Release

The inventors interestingly foresaw the potential of this drug-delivery technology for antipsychotic agents, natural and synthetic hormones, narcotic antagonists, vitamin B12, and peptides such as bacitracin, polymyxin B sulfate, and sodium colistimethate. Today, there are a number of PLGbased pharm...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutical technology Europe Vol. 29; no. 7; p. 22
Main Author Tice, Tom
Format Journal Article
LanguageEnglish
Published Monmouth Junction MultiMedia Healthcare Inc 01.07.2017
Subjects
Antibiotics
Antipsychotics
Birth control
Clinical trials
Drug delivery systems
Fertility
Growth hormones
Inventors
Laboratories
Peptides
Pharmaceutical industry
Polymer solubility
Polymers
Prostate cancer
Psychotropic drugs
Research centers
Researchers
Steroids
Studies
Transplants & implants
Online AccessGet full text

Cover

More Information
Summary:The inventors interestingly foresaw the potential of this drug-delivery technology for antipsychotic agents, natural and synthetic hormones, narcotic antagonists, vitamin B12, and peptides such as bacitracin, polymyxin B sulfate, and sodium colistimethate. Today, there are a number of PLGbased pharmaceutical products on the market that deliver many of the drug substances listed in the patent. A milestone occurred when a Southern Research Institute/Syntex team developed a phase-separation microencapsulation process for LHRH peptides that was much different from emulsion-based, solvent evaporation processes used to encapsulate steroids. Debiopharm, a Swiss-based biopharmaceutical company, recognized that controlled-release LHRH for the suppression of testosterone had greater potential for the treatment of prostate cancer than contraception. The product was launched as Lupron Depot (leuprolide acetate depot suspension) in 1989 (8), and it became a blockbuster drug with sales exceeding that of a liquid leuprolide product, which demonstrated the value of complex, extended-release parenteral products based on PLG excipients. The engulfed microparticles then release the vaccine antigen within these cells, triggering the cells to produce immunoglobulin antibody titres, which provide mucosal and T-cell responses. [...]polymer solubility varied from batch to batch, making it difficult to perform robust formulation processing and achieve reproducible drug-delivery performance from microparticles and implants. The future for PLG drug delivery The majority of biopharmaceutical drugs being developed today will require parenteral administration, and many of these compounds will require extended-release performance. R.L. Dunn, J.P. English, D.R. Cowsar, D.P. Vanderbuilt, inventors, Atrix Laboratories, Inc., assignee, Biodegradable in-situ forming implants and methods of producing the...
ISSN:1753-7967